Hi, what are you looking for?
Jewish Business News
Search results for "Mylan"
Business
Teva declined the chance because it does not operate in the store-brand OTC market, Perrigo's main activity.
Business
It's tictoc, tictoc, for Teva.
Business
Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE:...
Business
– Teva has lost its 180 days exclusivity for the generic version of Pfizer’s arthritis and chronic pain treatment. – The US Supreme...
Business
– Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and...
Business
– Leading Israeli Pharmaceutical company Teva has mixed results in its initial U.S. Supreme Court hearing over the possible loss of patent protection for...
Business
– Teva is battling generic versions of the 20 mg and 40 mg dosages of its MS blockbuster. – In the absence of...
Business
– Barclays analyst Douglas Tsao sees the success of double-dose Copaxone as a platform for expansion. – “The mergers and acquisition phenomenon is one...
Court
– – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7, 132, 570...
Court
– Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex Capsules. – – Teva Pharmaceutical Industries...